Govorestat Shows Promising Results in CMT1A Clinical Trial
Applied Therapeutics presented 12, 18, and 24-month results from the INSPIRE Phase 2/3 trial of govorestat for Charcot-Marie-Tooth Sorbitol...
Intellia Announces Positive Two-Year Data From Ongoing Phase 1 Study of NTLA-2002 for ATTR Amyloidosis
Intellia Therapeutics announced positive two-year follow-up data from its Phase 1 trial of nexiguran ziclumeran (nex-z) for hereditary ATTR...
Silo Pharma Selects Veloxity Labs for Bioanalytical Study
Silo Pharma (Nasdaq: SILO), a biopharmaceutical company developing novel therapeutics and drug delivery systems, has partnered with Veloxity Labs...
Vaxart Oral Norovirus Vaccine Data in Science Translational Medicine
Vaxart announced complete Phase 2b results for its oral norovirus vaccine candidate, demonstrating safety and efficacy against infection. The...
Meiragtx Showcases Gene & Cell Therapy Advances at ASGCT 2025
MeiraGTx Holdings plc will present four posters at the 2025 ASGCT Annual Meeting, showcasing advancements in gene therapy for...
ABSCI Announces First Participants Dosed in Phase 1 Trial of ABS-101
Absci Corporation, a clinical-stage biopharmaceutical company, has initiated a Phase 1 trial of ABS-101, its AI-designed antibody for inflammatory...
Ascendis Pharma TransCon CNP Improves Growth, Bone Health in Children with Achondroplasia
Ascendis Pharma A/S released 52-week data from its ApproaCH trial, showing that TransCon CNP (navepegritide) improved growth and bone...
Seabreeze Study: Evaluating Medikibart for Asthma Exacerbations
Connect Biopharma has initiated its Phase 2 Seabreeze STAT Asthma study to evaluate rademikibart’s safety and efficacy as an...
Bucillamine Research for Nerve Agent Exposure: Revive Therapeutics Update
Revive Therapeutics is partnering with Defence R&D Canada (DRDC) to study Bucillamine as a potential treatment for nerve agent...
4-Year Data Shows Sustained Response to Transcon PTH Therapy
Ascendis Pharma A/S released 214-week data from its Phase 2 PaTH Forward Trial of TransCon PTH (palopegteriparatide) for adults...